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Abstract
Background: Axonal damage and loss substantially contribute to the incremental accumulation of clinical disability
in progressive multiple sclerosis. Here, we assessed the amount of Wallerian degeneration in brain tissue of multiple
sclerosis patients in relation to demyelinating lesion activity and asked whether a transient blockade of Wallerian
degeneration decreases axonal loss and clinical disability in a mouse model of inflammatory demyelination.
Methods: Wallerian degeneration and acute axonal damage were determined immunohistochemically in the
periplaque white matter of multiple sclerosis patients with early actively demyelinating lesions, chronic active
lesions, and inactive lesions. Furthermore, we studied the effects of Wallerian degeneration blockage on clinical
severity, inflammatory pathology, acute axonal damage, and long-term axonal loss in experimental autoimmune
encephalomyelitis using Wallerian degeneration slow (WldS) mutant mice.
Results: The highest numbers of axons undergoing Wallerian degeneration were found in the perilesional white
matter of multiple sclerosis patients early in the disease course and with actively demyelinating lesions.
Furthermore, Wallerian degeneration was more abundant in patients harboring chronic active as compared to
chronic inactive lesions. No co-localization of neuropeptide Y-Y1 receptor, a bona fide immunohistochemical marker
of Wallerian degeneration, with amyloid precursor protein, frequently used as an indicator of acute axonal transport
disturbance, was observed in human and mouse tissue, indicating distinct axon-degenerative processes.
Experimentally, a delay of Wallerian degeneration, as observed in WldS mice, did not result in a reduction of clinical
disability or acute axonal damage in experimental autoimmune encephalomyelitis, further supporting that acute
axonal damage as reflected by axonal transport disturbances does not share common molecular mechanisms with
Wallerian degeneration. Furthermore, delaying Wallerian degeneration did not result in a net rescue of axons in late
lesion stages of experimental autoimmune encephalomyelitis.
Conclusions: Our data indicate that in multiple sclerosis, ongoing demyelination in focal lesions is associated with
axonal degeneration in the perilesional white matter, supporting a role for focal pathology in diffuse white matter
damage. Also, our results suggest that interfering with Wallerian degeneration in inflammatory demyelination does
not suffice to prevent acute axonal damage and finally axonal loss.
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Background
Axonal damage and loss are the key structural features
in multiple sclerosis patients and the most important
correlates of persistent disability [1–3]. Also, the insidi-
ous clinical worsening in later stages of the disease,
often independent of newly formed lesions and largely
non-responsive to immunomodulatory treatments, but
reflected in important brain and cervical spinal atrophy,
is considered due to cumulative axonal loss [4–7].
Reports on axonal loss in the normal-appearing white
matter (NAWM) and spinal cord range from ∼20 to
55%, whereas in chronic multiple sclerosis lesions,
axonal reduction of up to 70% has been reported [8].
Axonal degeneration can occur via several mechanisms,
the most prominent being anterograde (or Wallerian) and
retrograde (“dying back”) degeneration [9]. Inflammation-
associated axonal transport disturbances, so-called “focal
axonal degeneration,” may precede axonal transection
and ensuing axonal self-destruction by Wallerian
degeneration [10].
Axonal transport disturbances, as visualized by the
accumulation of anterogradely transported proteins such
as amyloid precursor protein (APP) and synaptophysin,
are often used as indicators of “acute axonal damage,”
and the density of APP-positive axonal profiles is highest
in the earliest stages of multiple sclerosis lesion forma-
tion [2, 11, 12]. Axons with transport disturbance are
also present at relatively high density in the rims of
chronic active, smoldering lesions and may be found in
the NAWM [2, 13, 14]. Whether and to which extent
axonal transport disturbances are reversible or lead to
definite, irreversible axonal transection, is not yet clear.
Correlations of APP-positive axonal profiles with the
density of macrophages have been repeatedly shown for
early lesions; however, in chronic disease, also a correl-
ation with T cells was observed [2, 14–16].
In experimental models of inflammatory demyelination,
the accumulation of organelles and proteins in axons
corresponds to “focal axonal degeneration,” i.e., localized
axonal swelling. Importantly, a proportion of axons show-
ing focal axonal degeneration finally undergo transection
and degenerate [10]. In experimental autoimmune en-
cephalomyelitis (EAE), the progression to axonal transec-
tion is largely prevented by treatment with ROS/NOS
scavengers, and axonal morphology is restored in the ma-
jority of treated axons studied [17]. Demyelination is not a
prerequisite for focal axonal degeneration, supporting the
contribution of highly lipid-soluble reactive species to
axonal damage [10, 17–19]. Of note, however, chronic
axonal transport disturbances may lead to distal axonal
“malnutrition” and dying back, highlighting the import-
ance of early therapeutic intervention [17].
Axons proceeding from focally disturbed axonal trans-
port to axonal transection undergo a series of orderly
events, namely, an acute retraction process, both prox-
imally and distally, termed acute axonal degeneration,
followed by classical Wallerian degeneration of the distal
axon part [20]. Both processes are, at least in part, medi-
ated by similar molecular mechanisms and contribute to
the important physical “gap” between the proximal and
distal axon stump rendering regenerative attempts chal-
lenging. As of yet, it is not well understood when the ma-
jority of Wallerian degeneration, the final process of
axonal self-destruction, takes place in multiple sclerosis.
In particular, it has not been explored whether Wallerian
degeneration is abundant in the chronic disease stage of
the disease.
Thus, to better understand the dynamics of axonal
loss in patients with multiple sclerosis, we set out to
study the timing and extent of Wallerian degeneration
in patients with short- and long-standing disease
harboring early- and late-stage lesions. Furthermore,
experimentally, we strived to determine whether delay-
ing Wallerian degeneration helps to decrease inflamma-
tory axonal damage in a model of multiple sclerosis.
Our data indicate that axonal transection and ensuing
axonal self-destruction is most pronounced in the peri-
plaque white matter of patients with early demyelinat-
ing lesions. Of note, however, also the presence of
chronic active lesions associates with a high density of
neuropeptide Y-Y1 receptor (NPY-Y1R)-positive axonal
profiles, underlining the notion that focal demyelinated
lesions are the key contributors to axonal demise in the
periplaque and normal-appearing white matter. Experi-
mentally, we find that neither acute axonal damage nor
persistent axonal loss is ameliorated in focal EAE le-
sions in Wallerian degeneration slow (WldS) compared
to wild-type (WT) mice, indicating limited sharing of
molecular mechanisms between acute axonal transport
disturbance and Wallerian degeneration [21]. Our study
underlines the role of focal white matter lesions for axonal
loss in the NAWM of patients with multiple sclerosis and
supports the concept of early pharmacological interven-
tions to prevent highly vulnerable, transport-deficient
axons showing signs of focal axonal degeneration from
transection.
Methods
Brain tissue from patients with multiple sclerosis
We investigated paraffin-embedded archival brain tissue
from 17 autopsied multiple sclerosis patients and 14
biopsied patients diagnosed with inflammatory demye-
lination consistent with multiple sclerosis. A total of 34
[16] tissue specimens, which included non-demyelinated
white matter regions, were used for the study. All biopsy
samples analyzed contained non-demyelinated peripla-
que white matter (PPWM) areas contiguous with early/
late active (n = 6) or inactive (n = 9) lesions. For direct
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comparison, non-demyelinated white matter tissue adja-
cent to 5 active lesions, 7 chronic active, and 7 chronic in-
active lesions was analyzed in multiple sclerosis autopsy
tissue. All lesions fulfilled the criteria for the diagnosis of
multiple sclerosis [22]. Lesional activity was determined
using previously described criteria [23]. The biopsies
were performed in different neurosurgical centers to
exclude neoplastic or infectious diseases. Specimens
were sent to the Department of Neuropathology in
Göttingen, Germany, for a second opinion. The patients’
clinical characteristics are summarized in Table 1.
Brain tissue from stroke patients
Axonal transport disturbances and Wallerian degener-
ation are typical and abundant after brain ischemia. To
study the spatial relation of the two phenomena in a
prototypic human disease, we analyzed archival paraffin-
embedded brain biopsy tissue from four patients (three fe-
males, one male; median age = 54 years; range 49–63 years)
with ischemic stroke lesions. Lesions were characterized
by tissue necrosis as evidenced by massive axonal loss and
dense macrophage infiltration. Axonal swellings in a typ-
ical ischemic pattern were abundant at the lesion borders.
Mice
Female 8–10-week-old WldS (C57BL/6 OlaHsd) and
C57BL/6 mice were obtained from the Harlan Labora-
tories, UK. The WldS mouse strain is characterized by
an 85-kb tandem triplication on chromosome four that
occurred as a spontaneous mutation in the B6 strain in
the 1940s, leading to the expression of an Ube4b/
Nmnat chimeric protein. Mutant mice do not show a
spontaneous phenotype. All mice had free access to
water and chow and were included in the experiments
after at least 5 days of acclimatization.
EAE induction and clinical evaluation
EAE was induced by subcutaneous injection of 200 μg
myelin oligodendrocyte glycoprotein (MOG)-peptide35–55
emulsified in complete Freund’s adjuvant (CFA) contain-
ing 1 mg/ml inactivated Mycobacterium tuberculosis. Con-
trol mice were injected with CFA alone. Three hundred
nanogram pertussis toxin was injected i.p. at day 0 and
day 2 after immunization. Clinical deficits were
assessed daily by a blinded observer using the following
scoring system: 0=no symptoms, 0.5=partial tail paresis,
1.0=complete tail paralysis, 1.5=slight hind limb paresis,
2.0=distinct hind limb paresis, 2.5=severe hind limb
paresis, 3.0=complete hind limb paralysis, 3.5=slight
forelimb paresis, 4.0=tetraparesis, 4.5=moribund, and
5.0=death. Mice were euthanized when reaching a score
of 3.5.
Histopathology
At the end of the EAE experiments, animals were deeply
anesthetized and perfused with phosphate buffered saline
(PBS) (pH 7.4) followed by 4% paraformaldehyde (PFA) in
PBS. The spinal cords (SC) were dissected, and at least
eight transverse sections were embedded in paraffin. One
to three micrometer-thick sections were stained with
hematoxylin-eosin (HE), Luxol Fast Blue/periodic acid
Schiff ’s reagent (LFB/PAS), and Bielschowsky silver im-
pregnation to determine inflammation, demyelination,
and axonal loss. Immunohistochemistry (IHC) was per-
formed using the primary antibodies listed in Table 2. For
antigen retrieval, tissue slices were microwaved in 10 mM
citrate buffer (pH 6.0) 3 × 5 min. Bound antibodies were
visualized using an appropriate biotinylated secondary
antibody and an avidin-peroxidase-DAB technique.
Negative control sections were incubated without primary
antibodies or with irrelevant primary antibodies of the
respective isotypes. Slices were counterstained with hema-
laun and cover-slipped. Double fluorescence labeling with
two mouse monoclonal primary antibodies was carried
out as described previously [24].
Mouse sciatic nerve transection
Four female C57BL/6 mice were used to study sciatic
nerve axotomy. They were deeply anesthetized by intra-
peritoneal injection of ketamine hydrochloride (“Ketanest
Inresa,” 50 mg/ml, Inresa, Freiburg, Germany) mixed with
xylazine hydrochloride (“Rompun” 2%, Bayer, Leverkusen,
Germany) in a ratio of 2:1 (0.4 mg Ketanest and 2 mg
Rompun for each mouse). Skin and muscles above the
right femur were opened by fine scissors, and the sciatic
nerve was completely transected. Subsequently, muscle
and skin were closed by suture (Ethicon). The mice were
kept for 6 days under a 12-h dark-light cycle and given
food and water ad libitum. The animals were perfused
transcardially with PBS and 4% PFA, and the sciatic nerves
Table 1 Characteristics of multiple sclerosis patients included in
the study
Sex; female n = 16, male n = 15
Age; 47 years (median), 19–76 (range)
Clinical diagnosisa
Clinically isolated syndrome suggestive of multiple sclerosis; n = 9
(9 biopsies)
Primary progressive multiple sclerosis; n = 6 (6 autopsies)
Relapsing-remitting multiple sclerosis; n = 4 (4 biopsies)
Secondary progressive multiple sclerosis; n = 9 (1 biopsy, 8 autopsies)
Disease duration of biopsied patientsb; 42 days (median), 9–540 days
(range)
Disease duration of autopsied patientsb; 19 years (median), 6–34 years
(range)
aClinical course was not available for three autopsy patients
bTime from the first symptoms to biopsy/autopsy
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dissected. The contralateral nerves and a sciatic nerve
from an animal without axotomy served as controls.
Sciatic nerves were post-fixed in 4% PFA overnight and
embedded in paraffin. Microtome sections of 1–3 μm
thickness were de-paraffinized, pre-treated by cooking in
citrate buffer (pH 6) for 10 min, and subjected to IHC.
Data acquisition and analysis
Tissue sections were analyzed using an Olympus BX51
fluorescence microscope equipped with a DP71 CCD
camera (Olympus Optical Co, Ltd., Hamburg, Germany),
a Zeiss Cell Observer microscope with an AxioCam ICc 3
CCD camera (Carl Zeiss MicroImaging, Ltd., Göttingen,
Germany), or by confocal laser scanning microscopy with
a Fluoview 1000 Olympus microscope. Transverse spinal
cord (SC) sections at the cervical, thoracic, lumbar, and
sacral levels were used for quantitative analysis. The
extent of acute axonal damage of axons undergoing
Wallerian degeneration and the density of healthy
phosphorylated axons was calculated by counting APP
+, NPY-Y1R+, or SMI31+ profiles in spinal cross sec-
tions within at least five white matter lesions per mouse
at ×400 magnification using an ocular counting grid.
Counts are given as immunopositive axonal profiles per
square millimeter. Relative axonal densities within lesions
were determined in sections stained with Bielschowsky’s
silver impregnation by using an axonal counting grid with
25 cross-points [25]. The number of axons intersecting
with the crossing points was determined as a fraction of
the total number of cross-points at a magnification of
×1000, under oil immersion. The value obtained in con-
trol animals was set to 100%. The degree of axon reduc-
tion in the lesion is given as the percentage of axon
density compared with the control animals. To determine
the extent of demyelination, digital images of LFB/PAS-
stained SC cross sections were recorded through an
Olympus light microscope with a CCD DP71 camera at
×100 magnification. Using the computer program Cell^F
(Soft Imaging Systems®), demyelinated white matter areas
were measured, and the percentage with respect to total
white matter was calculated. The inflammatory index was
defined as the mean number of perivascular infiltrates
within the SC parenchyma of 8–10 spinal cross sections
per animal. All the images were prepared in Adobe Photo-
shop CS4 Version 11.0.2.
Statistical analysis
Statistical analyses were carried out using Microsoft
Office Excel 2007 and GraphPad Prism (GraphPad
Software, La Jolla, USA). After normality testing, an un-
paired t test was applied to determine potential differ-
ences in the mean clinical severity scores of WT and
WldS mice at day 20 and day 40 after disease onset.
Histological data were analyzed by the non-parametric
Mann-Whitney U test; animals in two groups (i.e., WldS
and WT) were compared on the basis of closely matched
clinical scores. The influence of genotype and disease
stage on inflammation and demyelination was determined
Table 2 Antibodies used for immunohistochemistry
Target Antibody type (clone) Dilution Pre-treatment Source
Amyloid precursor protein (APP) Mouse mAb
(22C11)
1:2000 Citrate MW Chemicon International, USA
Neuropeptide Y receptor Y1 (NPY-Y1R) Rabbit polyAb #96106 1:1000 Tris-EDTA MW CURE/UCLA, USA
Myelin basic protein (MBP) Rabbit polyAb 1:1000 None DakoCytomation, Denmark
MBP peptic fragment 70–89 Mouse mAb (SMI94) 1:5000 Steam Covance Inc., USA
Myelin proteolipid protein (PLP) Mouse mAb (Plpc 1) 1:500 Citrate MW Biozol, Germany
Myelin oligodendrocyte glycoprotein (MOG) Rat polyAb 1:1000 Citrate MW [75]
Myelin-associated glycoprotein (MAG) Rabbit polyAb 1:10 Citrate MW [76]
2′,3′-Cyclic-nucleotide 3′-phosphodiesterase
(CNPase)
Mouse mAb (SMI91) 1:200 Citrate MW Covance Inc., USA
Monocytes, activated microglia Mouse mAb (KiM1P) 1:5000 Citrate MW [77]
Early-activated macrophages (S100A9) Rabbit polyAb 1:500 Citrate MW [78]
Phosphorylated NFs Mouse mAb (SMI31) 1:10000 Citrate MW Covance Inc., USA
Non-phosphorylated NFs Mouse mAb (SMI32) 1:1000 Citrate MW Covance Inc., USA
Hypo-phosphorylated NFs Mouse mAb (SMI35) 1:10000 Citrate MW Covance Inc., USA
NF-low-molecular-weight (NF68) Mouse mAb (NR4) 1:100 Citrate MW Sigma Chemical Company, USA
NF-high-molecular-weight (NF200) Mouse mAb (N52) 1:400 Citrate MW Sigma Chemical Company, USA
Growth-associated protein 43 (GAP43) Mouse mAb (9-1E12) 1:4000 Citrate MW Chemicon International, USA
Synaptophysin (protein p38) Mouse mAb (SY38) 1:10 Citrate MW DakoCytomation, Denmark
NF neurofilament, mAb monoclonal antibody, polyAb polyclonal antibody, MW microwave pre-treatment
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using a two-way-ANOVA. Statistical significance was
defined as p < 0.05. All quantitative morphological data
are expressed as mean ± standard error of the mean
(SEM) in the EAE studies.
Results
Prevalence of Wallerian degeneration in patients with
early- and late-stage multiple sclerosis
Wallerian degeneration is thought to reflect a clinically
relevant component of disability and disease progression
in multiple sclerosis. However, the contribution of
Wallerian degeneration to multiple sclerosis pathology is
not yet known. Here, we studied the occurrence and
extent of Wallerian degeneration in biopsy multiple
sclerosis tissue from patients with short duration as well
as in autopsied patients with chronic multiple sclerosis.
Using NPY-Y1R immunohistochemistry, Wallerian de-
generation was quantified in areas of PPWM brain tissue
from 31 multiple sclerosis patients. We observed wide-
spread occurrence of NPY-Y1R+ degenerating axonal fi-
bers in non-demyelinated PPWM areas in multiple
sclerosis patients (Fig. 1). Patients were divided into
early and chronic disease groups according to disease
duration, i.e., time from the first symptoms to biopsy/
autopsy. The number of NPY-Y1R+ axons in multiple
sclerosis PPWM was significantly higher in the early as
compared to the chronic disease stage (early; 113.6 ± 7,
chronic; 4.6 ± 0.8 profiles/mm2; ***p < 0.001). In early
multiple sclerosis, the number of axons undergoing Wal-
lerian degeneration was significantly higher in PPWM
connected to active lesions as compared to early inactive
lesions (PPWM-active; 129.1 ± 5, early inactive; 85.9 ± 5
profiles/mm2; **p < 0.01). Indeed, even in chronic disease
stages, the number of axons undergoing Wallerian
degeneration was significantly lower in PPWM areas of
chronic inactive lesions (1.4 ± 0.6 profiles/mm2) compared
Fig. 1 Wallerian degeneration is most frequent in the PPWM of lesions with ongoing demyelinating activity. NPY-Y1R IHC was performed on multiple
sclerosis biopsy and autopsy tissue samples containing active, early inactive, chronic active, and chronic inactive lesions (a–e). Double IHC of NPY-Y1R
(red, a) with the pan-macrophage marker KiM1P (blue, a) showed very little evidence for Wallerian degeneration (arrows) in the actively demyelinating
lesion edge of a multiple sclerosis biopsy (a, inset). The density of NPY-Y1R+ axonal profiles indicating Wallerian degeneration was significantly higher
in PPWM areas of active and chronic active lesions compared to early inactive and chronic inactive lesions in both early and chronic multiple sclerosis
patients (f). Significantly higher numbers of NPY-Y1R+ axonal profiles (arrows) were detected in the PPWM of early multiple sclerosis patients
(biopsies; a–b, f) compared to chronic multiple sclerosis patients (autopsies; c–f). Error bars=SEM, *p < 0.05, **p < 0.01, ***p < 0.001. Scale bars;
a 100 μm; b 25 μm, c–e 50 μm; (inset a, e) 10 μm
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to PPWM of active (6.8 ± 1.3 profiles/mm2; **p < 0.01),
and chronic active lesions (5.1 ± 0.9 profiles/mm2; *p =
0.03). Our findings in brains of patients with multiple
sclerosis indicate a high incidence of Wallerian degener-
ation in early stages of multiple sclerosis, which may be
related to axonal transections in focal demyelinated
lesions.
No difference in MOG35–55 EAE course and severity
between WldS and WT mice
To assess the impact of the WldS fusion gene on inflam-
matory disease severity, MOG35–55 EAE was induced in
WldS mutant and WT C57BL/6 mice. No statistically sig-
nificant difference in disease severity, i.e., mean disease
score ± SD (standard deviation) was observed between
WldS and WT mice on specifically testing the acute (day
20, p = 0.94) and chronic (day 40, p = 0.85) disease phase
(Fig. 2) [26]. Also, the mean maximal cumulative score
40 days after disease onset was comparable in WT (2.5 ±
0.32) and WldS (2.31 ± 0.28) mice. A qualitative histo-
pathological analysis revealed an increase in lesion sizes
from day 20 to day 40 after disease onset in both experi-
mental groups. Experiments were repeated at least three
times, and consistent results were obtained.
Analysis of inflammation and demyelination in MOG35–55-
induced EAE in WldS and WT mice
Differences in lesion acuteness and extent of inflammation
and demyelination might obscure differences in the extent
of axonal vulnerability between the two mouse strains.
We thus examined the number of perivascular and subpial
inflammatory infiltrates per SC cross section (inflamma-
tory index) and the percentage of demyelinated white
matter in WldS vs. WT mice with acute EAE (Fig. 3a–f ).
The mean inflammatory index was 4.8 ± 0.8 in WldS and
4.9 ± 0.7 in WT mice (Fig. 3c); the mean demyelinated
white matter area was 5.4 ± 1.3% in WldS and 5.7 ± 0.7%
in WT mice (Fig. 3f). Inflammatory index and demyelin-
ation after immunization with MOG35–55 in Wld
S and
WT mice were thus virtually the same, making a direct
comparison of axonal pathology between the two mouse
strains possible [27]. To ensure that lesions with similar
inflammatory demyelinating activity were examined for
axonal damage and loss, IHC for the early macrophage ac-
tivation antigen S100A9 was performed, and all animals
were found to have active lesions with recent monocyte
invasion [28]. Also, morphometry on H&E and LFB/PAS
stained sections of WldS and WT mice with chronic EAE
revealed no significant differences with regard to inflam-
mation (mean inflammatory index WldS; 1.3 ± 0.5 and
WT; 1.4 ± 0.3 inflammatory infiltrates per spinal cord
cross section) or demyelination (mean demyelinated white
matter WldS; 3.3 ± 1.2% and WT; 2.7 ± 0.9%) between the
strains (Fig. 3g-l). However, a significant decrease in the
extent of inflammation and a trend towards reduced de-
myelination from day 20 to day 40 after disease onset was
observed for both experimental groups (two-way ANOVA;
inflammatory index, F (1, 25), p = 0.0002); demyelination,
F (1, 25), p = 0.0519).
Similar amount of acute axonal damage in WldS and WT
EAE mice
The clinical deficit in an acute inflammatory demyelinat-
ing disease may not reflect the extent of structural axonal
damage due to the effects of cytokines and edema on ion
homeostasis and axonal conduction. In fact, elevated cyto-
kine levels in the CNS could affect neuroaxonal function
and may at least be partly responsible for the clinical man-
ifestations during acute exacerbation of multiple sclerosis
and EAE [29, 30]. Therefore, to identify the extent of acute
axonal damage in WldS mutant and WT mice, we applied
antibodies to APP (Fig. 4a–d) to visualize axons with
impaired axonal transport. In the acute as well as chronic
disease stage, the densities of APP+ axonal profiles in in-
flammatory demyelinated lesions did not differ between
WldS and WT mice [WldS; 370 ± 58, WT; 424 ± 37 APP+
profiles/mm2 (acute, p = 0.46); WldS; 350 ± 47, WT; 387 ±
64 APP+ profiles/mm2 (chronic, p = 0.79)], thus indicating
that axons are damaged to a similar degree in both mouse
strains, irrespective of the genotype and disease phase
(Fig. 4e).
Less Wallerian degeneration in the acute stage of EAE in
WldS mutant mice
As characterized previously [31, 32], the NPY-Y1R anti-
serum recognized elongated and ovoid axonal structures
in WldS and WT EAE mice (Fig. 4f–g). In acute disease,
Fig. 2 The WldS mutation does not influence the clinical severity of
EAE. EAE severity in WldS (n = 18) and WT (n = 19) mice was similar in
both the acute and chronic disease stage. Mean disease score ± SD
during 40 days after disease onset are shown. The graph contains
scores from three independent experiments. The days after
development of the first clinical symptoms are plotted on the x-axis
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a mean of 67 ± 13 NPY-Y1R+ axonal profiles/mm2 in WldS
mutant mice and 1153 ± 241 NPY-Y1R+ axonal profiles/
mm2 in WT mice were detected (Fig. 4f–g and j), indicating
markedly reduced Wallerian degeneration in WldS mice in
the acute phase of the disease (*p= 0.02). In contrast, no sig-
nificant difference in Wallerian degeneration was observed
in the chronic disease phase; 535 ± 154 NPY-Y1R+ axonal
profiles per square millimeter were detected in WldS mice
and 633 ± 164 per mm2 in WldS mice (p= 0.69) (Fig. 4h–j).
Intriguingly, a significant increase in the densities of NPY-
Y1R+ axonal profiles was observed in chronic WldS EAE
mice as compared to the acute stage (*p= 0.03). This im-
plies that axon degenerative mechanisms in WldS mice are
averted primarily during the acute stage of an autoimmune
inflammatory demyelinating attack.
NPY-Y1R immunoreactivity specifically identifies Wallerian
degeneration in EAE and stroke
To examine whether the Wallerian degeneration-induced
expression of NPY-Y1R is associated with degenerating
Fig. 3 Similar extent of inflammation and demyelination in WldS and WT mice in acute and chronic MOG35–55-EAE. The mean number of
inflammatory infiltrates per spinal cord (SC) cross section (H&E; a–c; g–i), and the percentage of demyelinated white matter (LFB/PAS; d–f; j–l) did
not differ between WldS and WT mice in the acute as well as the chronic disease stage (d20 and d40). Error bars=SEM. Scale bars=(a, b, d, and e)
100 μm; (g, h, j, and k) 200 μm
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Fig. 4 Similar extent of acute axonal damage but markedly reduced Wallerian degeneration in WldS mice with acute EAE. Comparable densities
of APP+ axonal profiles were found in spinal EAE lesions of WldS and WT mice in both the acute and chronic disease stage (a–e). In contrast,
significantly fewer NPY-Y1R+ axonal profiles were observed in WldS as compared to WT mice in acute EAE (f–g and j). In the chronic stage, the
densities of NPY-Y1R-immunoreactive axonal profiles were comparable between WldS and WT mice (h–j). Error bars=SEM, *p < 0.05, n = 15 animals
per group. Scale bars=(a–b) 100 μm; (inset b) 50 μm; (c–d) 200 μm; (f–g) 150 μm; (h–i) 200 μm
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axonal structures, immunofluorescence double label-
ings were performed in mouse EAE lesions (Fig. 5). We
observed only rarely a co-localization of NPY-Y1R immu-
noreactivity with accumulated APP in axons (Fig. 5a–c).
Also, NPY-Y1R expression did not co-localize with phos-
phorylated neurofilaments (NFs) of healthy axons detected
by the SMI31 antibody (Fig. 5d–f), dephosphorylated NFs
of damaged axons detected by the SMI32 antibody
(Fig. 5g–i), and the low-molecular-weight NF-68
(Additional file 1). Hypophosphorylated NFs found in
normal axons recognized by the SMI35 antibody were
only occasionally co-localized with NPY-Y1R+ axons
(Additional file 1). However, substantial co-localization
of NPY-Y1R was observed with the high-molecular-
weight NF-200, detected by the N52 antibody (Fig. 5j–l,
Table 2). Besides axonal degeneration, Wallerian degen-
eration is characterized by disintegration of myelin with
the formation of the pathognomonic myelin ovoids
[33]. Hence, to assess whether the antigen detected by
the anti-NPY-Y1R antiserum is associated with myelin
Fig. 5 NPY-Y1R does not co-localize with markers of axonal transport disturbance, neurofilament dephosphorylation or myelin proteins in
EAE lesions. Immunofluorescence double labeling performed on EAE lesions in WT mice revealed only rare co-localization of NPY-Y1R
(red) and early axonal transport deficits indicated by APP accumulation (green) (a–c, arrow). NPY-Y1R immunoreactivity also did not co-
localize with phosphorylated neurofilaments (NF) of healthy axons (SMI31, green) (d–f) or de-, resp. non-phosphorylated NF predominantly
found in damaged axons (SMI32, green) (g–i), but partly with the NF high molecular weight (NF-200, green) subunit (j–l, arrows). Double IHC of NPY-
Y1R (n, red) with MBP (m, green) did not reveal any co-localization (o, inset). Inset in (o) shows NPY-Y1R+ axons, in part enwrapped by myelin, at high
magnification (arrows). Scale bars=(a–o) 200 μm; (inset o) 10 μm
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ovoids, we performed fluorescent double IHC with
antibodies against myelin basic protein (MBP), myelin
proteolipid protein (PLP), MOG, myelin-associated
glycoprotein (MAG), and 2′,3′-Cyclic-nucleotide 3′-
phosphodiesterase (CNPase) in spinal EAE lesions from
WT mice (Fig. 5m–o, Additional file 2). NPY-Y1R did
not co-localize with any of the myelin proteins. In
addition, to test whether this spatial co-localization pat-
tern is also observed in areas of Wallerian degeneration
after stroke, human ischemic brain lesions were
double-labeled for NPY-Y1R and axonal markers (data
not shown). In line with our findings in mouse EAE,
co-localization of NPY-Y1R and NF-200 was observed,
but not of NPY-Y1R and APP or SMI32.
NPY-Y1R+ axonal structures are enwrapped by myelin in
early experimental sciatic nerve transection
Wallerian degeneration after mouse sciatic nerve axotomy
features a rapid degeneration of axons during the first
6 days after injury [34, 35]. Double immunofluorescence
on mouse sciatic nerve 6 days after transection showed
significantly more elongated and ovoid NPY-Y1R+ axonal
structures enwrapped by MBP+ myelin sheaths than
degenerated axons lacking any myelin (Additional file 3).
This further supports that NPY-Y1R expression is present
on axonal structures, but not myelin, in both the CNS
and PNS, thus identifying comparatively early stages of
Wallerian degeneration.
Axonal loss is similar in WldS and WT mice in the chronic
disease phase
We hypothesized that the lower numbers of axons
undergoing Wallerian degeneration in the early disease
stage might lead to less net axonal loss in established
EAE lesions of WldS mice. Healthy SMI31+ axons as well
as relative axonal densities (Bielschowsky silver impreg-
nation) were determined in EAE lesions (Fig. 6). In the
acute stage, the number of healthy SMI31+ axons was
significantly higher in WldS compared to WT lesions
(WldS; 2658 ± 335, WT; 1156 ± 265 SMI31+ profiles/
mm2; *p = 0.02), whereas the counts were very similar in
the chronic stage (WldS; 193 ± 21, WT; 173 ± 14 SMI31+
profiles/mm2; p = 0.39) (Fig. 6a and c). Furthermore, the
densities of healthy axons in both genotypes were sig-
nificantly higher in the acute compared to the chronic
stage (WldS; *p = 0.03; WT; *p = 0.01). Importantly,
axons after an inflammatory attack may become dephos-
phorylated but do not necessarily vanish. Therefore, we
next quantified axons in defined lesion areas after
Bielschowsky silver impregnation (Fig. 6b and d). Rela-
tive axonal densities were significantly higher in WldS
mice than WT mice in the acute stage (WldS; 91.52 ±
2.3%, WT; 76.34 ± 2.3%; *p = 0.04) but virtually identical
in the chronic stage (WldS; 56.8 ± 8.4%, WT; 55.1 ±
11.6%; p = 0.93). Moreover, comparable with the SMI31+
counts, relative axonal densities of silver impregnated
axons in WldS mice were significantly lower in the
chronic than in the acute stage (*p = 0.03). This clearly
indicates that the WldS mutation did not protect against
long-term inflammatory axonal loss. Hence, consistent
with other CNS lesion paradigms tested [36–38], our
results suggest that also in inflammatory demyelination,
Wallerian degeneration is merely slowed down or delayed
inWldS mice.
Markers for axonal regeneration and synaptic plasticity
are not co-expressed with NPY-Y1R in degenerating
axons
De- and regenerative processes in axons may be closely
related. We thus tested whether markers putatively
associated with axonal regeneration are co-expressed
with NPY-Y1R. Growth-associated protein 43 (GAP43)
and synaptophysin (Syn) are synaptic proteins that are
associated with axonal sprouting and synaptogenesis in
various neurodegenerative diseases and may accumulate
in regenerating neurons and axons. Therefore, expres-
sion of GAP43 and Syn in damaged axons could reflect
a regenerative attempt [24]. However, immunofluores-
cence double labelings on WT EAE spinal lesions did
not reveal any co-localizations of NPY-Y1R with GAP43
(Additional file 4 A-C) or Syn (Additional file 4 D-F).
Discussion
The extent of axonal loss is the most important pre-
dictor of permanent clinical deficits in multiple sclerosis
[39–41]. Wallerian degeneration of axons transected in
focal inflammatory demyelinated lesions contributes to
the loss of neural structures. Here, we demonstrate a
clear relationship between lesion demyelinating activity
and Wallerian degeneration in non-demyelinated mul-
tiple sclerosis white matter. Furthermore, we find that
the extent of Wallerian degeneration is most extensive
in early disease stages supporting the interrelation be-
tween inflammation and neurodegeneration in multiple
sclerosis [24, 42, 43]. In addition, in the present study,
we hypothesized that WldS mutant mice would present
with less axonal damage and reduced disability in
MOG35–55 EAE compared to WT mice. However, sur-
prisingly, WldS and WT mice showed a similar disease
course, and the degree of inflammation, demyelination,
and acute axonal damage was comparable in the early as
well as in the more advanced disease stage. Immunohis-
tochemical staining with the anti-NPY-Y1R antibody
demonstrated abundant Wallerian degeneration in WT
mice in the early and chronic disease stage but identified
only very few axons undergoing Wallerian degeneration
in WldS mice in the acute disease stage. Furthermore, the
net axonal loss was comparable in the chronic disease
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Fig. 6 Less axonal loss in the acute disease phase in WldS mutant mice. SC cross sections of WldS mutant and WT mice with EAE were stained
with anti-SMI31 antibody (a) and Bielschowsky’s silver impregnation (b) showing axonal loss in white matter lesions 20 days (acute) and 40 days
(chronic) after disease onset. Quantification of SMI31+ phosphorylated axons revealed that the densities of intact healthy axons were significantly
higher in WldS mice as compared to WT mice in acute stage disease (a i–ii, c). However, similarly dense SMI31+ profiles were observed in the
chronic stage (a iii–iv; lateral funiculus, c). Densities of SMI31+ profiles significantly decreased in both WldS and WT mice from the acute to the
chronic disease stage (a, c). Similarly, Bielschowsky’s silver impregnation displayed significantly higher relative axonal densities in WldS mice only
in the acute stage (b i–ii, d); again, axonal loss in WldS mice was significantly more pronounced in the chronic than in the acute disease stage
(b, d). Yellow and red boxes in (a i–ii) are higher magnifications of lesion areas with SMI31 immunostaining in acute disease. Error bars=SEM,
n = 15 animals per group, *p < 0.05. Scale bars=(a i–ii) 100 μm; (a iii–iv, b i–ii) 150 μm; (b iii–iv) 200 μm; (insets a i–ii) 25 μm
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stage in both genotypes. Our data thus indicate that the
WldS gene markedly delays Wallerian degeneration after
inflammatory axonal damage but does not ameliorate dis-
ability resulting from EAE or cumulative axon loss.
Previous studies investigating axotomy-induced CNS
Wallerian degeneration proposed three distinct phases:
first, the sudden fragmentation (after 10–20 min) of both
the distal and proximal axon close to the site of injury;
second, the slow axonal retraction resulting in bulb forma-
tion at the axon ends with the distal stump remaining ana-
tomically integrated and functional, and third, a proximal
stable fragment while the distal fragment undergoes
secondary degeneration, i.e., swelling, connection thin-
ning, and rapid granularization [20, 44–47]. Convincing
evidence for the distinct molecular basis of these pro-
cesses was recently obtained in studies performed in WldS
mutant mice. Kerschensteiner and colleagues could show
that the WldS mutation prevented the onset of sudden
fragmentation in transected CNS axons [20]. Also, expres-
sion of the WldS gene remarkably protracted the slow re-
traction phase in which the axon distal to the transection
site remains morphologically intact and retains its physio-
logic function [34, 38, 48, 49].
Modulation of ion channels expressed in axons under
inflammatory demyelinating conditions was shown to
amend axonal degeneration [50–52]. Interestingly, it has
been demonstrated that Wallerian degeneration of the dis-
tal stump is a Ca2+-mediated process [53, 54]. The rise in
intra-axonal ROS production in the distal stump after
transection is diminished in the WldS mutation, which
thus may entail preserved mitochondrial function and en-
ergy supply [55]. Hence, the fast fragmentation and slow
retraction, but not the late rapid granularization, are ROS
dependent. This is in agreement with the notion that the
delay in axonal degeneration observed in WldS axons is
only transient. Mitochondrial dysfunction, energy failure,
and ensuing Ca2+ overload have been implicated as the
final common pathways in inflammatory axonal damage,
leading to the activation of intra-axonal proteases, cyto-
skeletal degradation, and axonal degeneration and loss
[56, 57]. Therefore, the WldS mutation might be well
suited to protect axons in an inflammatory demyelinating
milieu, even beyond its well-described effect on the clas-
sical axonal self-destruction after transection. In our
study, however, the densities of acutely damaged axons in
inflammatory lesions were similar in WldS and WT mice,
in both the acute and chronic disease stages, suggesting
that the inflammatory insult surpassed the axonoprotec-
tive capacities of the WldS phenotype.
Our data show that the occurrence of Wallerian de-
generation in multiple sclerosis is related to the density
of axons with transport deficits observed in the tissue:
Wallerian degeneration is most abundant in the peripla-
que white matter of patients early in the disease course
harboring macrophage-rich focal lesions with ongoing
myelin degradation. To the contrary, only few axons
undergoing Wallerian degeneration were observed in
late-stage patients with predominantly chronic inactive
lesions. Noteworthy and as reported previously, chronic
active lesions represent an area of ongoing demyelin-
ation and focal axonal degeneration [2, 14, 58]. In line,
elevated levels of axons undergoing Wallerian degener-
ation were detected in the corresponding periplaque and
normal-appearing white matter. Although our work
cannot definitely exclude the presence of focal axonal
degeneration in non-lesional areas, it clearly shows that
the extent of Wallerian degeneration is related to focal
demyelinating pathology. Furthermore, our work high-
lights the relevance of axonoprotective treatments, also
in patients with more advanced disease, where smolder-
ing lesions are most common.
Coleman and colleagues [59, 60] observed that the
WldS mutation also inhibits degenerative axonal swell-
ings in gracile axonal dystrophy (gad) mice, a mutant
mouse strain characterized by a “dying-back” type axonal
degeneration and the formation of axonal spheroids. In
contrast, we studied axonal pathology under inflamma-
tory demyelinating conditions. NOS and ROS released
by activated macrophages have been implicated in acute
axonal transport disturbance, even in myelinated axons,
and may contribute to mitochondrial damage and Ca2+
overload, leading to a vicious cycle of energy failure and
cytoskeletal degradation [10]. Our results suggest that
the intra-axonal protective mechanisms operating in WldS
mice, e.g., antioxidation and increased Ca2+ buffering
capacity, are not sufficient to prevent or diminish axonal
swellings during a myelin-specific T cell-mediated auto-
immune attack. Prior studies showed that the WldS pro-
tection mechanism is intrinsic to the axon [47, 61, 62].
However, recently, an upregulation of CD200 was ob-
served in WldS mice, which may play a critical role in
reducing microglia-mediated neuroaxonal damage in
the CNS [63–65]. Taken together, our results indicate
that in inflammatory demyelination, axonal transport
deficits and cumulative loss of axons are not restrained
in WldS mice.
Irrespective of disease-related or mechanical transec-
tion of axons, the common downstream mechanisms of
axonal degeneration include energy failure, increased
Ca2+ influx and activation of calpains, resulting in the
degradation of axon components [66–68]. As early as in
the 1980s, it has been shown that NPY along with its Y1
receptor modulates increased Ca2+ concentrations in
cultured dorsal root ganglion (DRG) neurons [69, 70].
NPY is widely distributed in the CNS and PNS, albeit
NPY and its receptor Y1 are not expressed in the same
population of neurons. However, both are upregulated in
axonal processes of DRG neurons after nerve injury in
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rodents [71–74]. It seems therefore possible that NPY-
Y1R plays a role in limiting the early destructive pro-
cesses in damaged axons. In this study, we observed an
important delay in NPY-Y1R expression in axons of
WldS mice with EAE, which is in line with the reduced
Ca2+ influx in transected WldS axons. Intriguingly, the
increased Ca2+ buffering capacity of WldS mitochondria
shows a gradual decrease over time in the distal stump
[53]. Hence, the intra-axonal protective mechanisms ap-
pear to decrease with time after transection in WldS
axons. Indeed, we observed substantially decreased im-
munoreactivity of NPY-Y1R in inflammatory SC lesions
of WldS mice in the acute stage as compared to the
chronic stage. Our results thus support the use of anti-
NPY-Y1R antibodies as a bona fide marker for Wallerian
degeneration.
Conclusions
The present study provides evidence that axonal degen-
eration in multiple sclerosis is closely related to the oc-
currence of focal axonal transport disturbances, to
focal demyelination and thus to phagocyte activation.
Our experimental data indicate that the WldS pheno-
type does not prevent axonal swellings in inflammatory
demyelination and fails to provide sufficient long-term
protection of CNS axons in a model of multiple scler-
osis. Although we observed an important delay in Wal-
lerian degeneration, this did not result in disease
attenuation or a net rescue of axons in WldS mice.
Hence, in our model, a delay in Wallerian degeneration
does not correlate with immediate clinical amelioration
of inflammatory axon damage. Further molecular stud-
ies into the axonoprotective mechanisms elicited in the
WldS mutant are required to find a way to impede
axonal degeneration and eventually restore axonal in-
tegrity and function.
Additional files
Additional file 1: NPY-Y1R+ axon undergoing Wallerian degeneration
do not co-localize with hypophosphorylated and low-molecular-weight
NF in EAE. Double-labeling fluorescent IHC reveals that NPY-Y1R+
degenerating axons are only rarely labeled with antibodies recognizing
hypophosphorylated NF (SMI35) (A-C). No colocalization is observed with
the 68 kDa low-molecular-weight NF (D-F) in WT EAE lesional and
perilesional tissue. Scale bars=(A-F) 100 μm. (JPG 343 kb)
Additional file 2: Axons undergoing Wallerian degeneration are at
least in part myelinated in EAE lesions. No co-localization of NPY-Y1R
immunoreactivity with myelin proteins, i.e., PLP (A-C), MOG (D-F), MAG
(G-I), and CNPase (J-L) was observed by fluorescence double IHC in WT
EAE mice, which further confirms that the antiserum against NPY-Y1R
applied does not detect an antigen situated within the myelin sheath
or myelin ovoids. Insets in (A-C) represent NPY-Y1R+ degenerating
fiber(s) in largely intact myelinated tracts, as determined by anti-PLP
IHC. Scale bars=(A-L) 200 μm; (insets A-C) 10 μm. (JPG 673 kb)
Additional file 3: NPY-Y1R IHC labels myelin ovoids typical of Wallerian
degeneration in mouse sciatic nerve transection. Elongated, beaded NPY-Y1R+
(red, A) axonal structures surrounded by MBP+ myelin sheaths (green, B) are
seen in longitudinal sections of mouse sciatic nerve 6 days after and distal to
the transection (C, arrows). Oil-immersion magnification (×1000) revealed that
NPY-Y1R+ axons were enwrapped with myelin (MBP) indicating myelin
ovoid formation, typical of Wallerian degeneration (D-F). (p < 0.05; G). Scale
bars=(A-C) 100 μm; (D-F) 20 μm. (JPG 1484 kb)
Additional file 4: Neuroaxonal regenerative markers are not co-
expressed in axons undergoing Wallerian degeneration. Axonal structures
immunopositive for GAP43 (A-C) and Synaptophysin (Syn) (D-F) did
not co-localize with NPY-Y1R+ degenerating axons in WT EAE lesions
by immunofluorescent double labeling. Syn expression was mostly
limited to gray matter regions of the SC in WT EAE. Scale bars=(A-F)
100 μm. (JPG 816 kb)
Abbreviations
APP: Amyloid precursor protein; EAE: Experimental autoimmune
encephalomyelitis; NAWM: Normal-appearing white matter; NPY-
Y1R: Neuropeptide Y-Y1 receptor; PPWM: Periplaque white matter;
WldS: Wallerian degeneration slow
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